Journal of Antimicrobial Chemotherapy (2003) 51, ii45-ii53
© 2003 The British Society for Antimicrobial Chemotherapy
Supplement |
Safety and tolerability of linezolid
Department of Infection, Guy’s and St Thomas’ Hospital and King’s College, London SE1 7EH, UK
Abstract
Clinical trials have shown that linezolid (600 mg twice daily in adults) is safe and generally well tolerated for up to 28 days. Drug-related adverse events, which are typically mild to moderate in intensity and of limited duration, include diarrhoea, nausea and headache in adults, and diarrhoea, loose stools and vomiting in children. Clostridium difficile-related complications with linezolid are uncommon. Linezolid is a weak, reversible monoamine oxidase inhibitor: foods containing high concentrations of tyramine should be avoided, and linezolid should be used with caution in patients taking adrenergic or serotonergic agents or in those with uncontrolled hypertension. In the majority of patients, linezolid has minimal adverse effects on blood chemistry or haematology. There have been case reports of reversible thrombocytopenia, anaemia and neutropenia associated with linezolid therapy. In Phase III studies, 2.4% of patients treated with linezolid and 1.5% of patients treated with comparator drugs developed reversible thrombocytopenia (P = 0.066), but there was no evidence of an increased risk of agranulocytosis, aplastic anaemia or other irreversible blood dyscrasias. Reduced platelet counts were associated with linezolid treatment for 
2 weeks; complete blood counts should be monitored weekly in patients receiving linezolid for more than 14 days and treatment should be discontinued if there is evidence of myelosuppression.
Footnotes
* Tel: +44-20-7928-9292, ext 3244; Fax: +44-20-7928-0730; E-mail: Gary.French{at}kcl.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Condos, N. Hadgiangelis, E. Leibert, G. Jacquette, T. Harkin, and W. N. Rom Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis Chest, July 1, 2008; 134(1): 187 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Corbett and J. A. Rebuck Medication-Related Complications in the Trauma Patient J Intensive Care Med, March 1, 2008; 23(2): 91 - 108. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Plock, C. Buerger, C. Joukhadar, S. Kljucar, and C. Kloft Does Linezolid Inhibit Its Own Metabolism? Population Pharmacokinetics As a Tool to Explain the Observed Nonlinearity in Both Healthy Volunteers and Septic Patients Drug Metab. Dispos., October 1, 2007; 35(10): 1816 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. I. Mortin, T. Li, A. D. G. Van Praagh, S. Zhang, X.-X. Zhang, and J. D. Alder Rapid Bactericidal Activity of Daptomycin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Peritonitis in Mice as Measured with Bioluminescent Bacteria Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1787 - 1794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I-N. Park, S.-B. Hong, Y.-M. Oh, M.-N. Kim, C.-M. Lim, S. D. Lee, Y. Koh, W. S. Kim, D. S. Kim, W. D. Kim, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis J. Antimicrob. Chemother., September 1, 2006; 58(3): 701 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Zivkovic and D. Lacomis Severe sensory neuropathy associated with long-term linezolid use Neurology, March 8, 2005; 64(5): 926 - 927. [Full Text] [PDF]
|
|
|
|
|
|
B. Spellberg, T. Yoo, and A. S. Bayer Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6 J. Antimicrob. Chemother., October 1, 2004; 54(4): 832 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Senneville, L. Legout, M. Valette, Y. Yazdanpanah, F. Giraud, E. Beltrand, G. Obert, L. Dubreuil, H. Migaud, and Y. Mouton Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study J. Antimicrob. Chemother., October 1, 2004; 54(4): 798 - 802. [Abstract] [Full Text] [PDF]
|
|